Konstantin Umanskiy to Gastrointestinal Agents
This is a "connection" page, showing publications Konstantin Umanskiy has written about Gastrointestinal Agents.
Connection Strength
0.293
-
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
Score: 0.154
-
The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509.
Score: 0.140